KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Notes Payables (2016 - 2017)

Teva Pharmaceutical Industries (TEVA) has disclosed Notes Payables for 6 consecutive years, with $15.0 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Notes Payables fell 80.0% year-over-year to $15.0 million, compared with a TTM value of $15.0 million through Dec 2016, down 80.0%, and an annual FY2016 reading of $15.0 million, down 80.0% over the prior year.
  • Notes Payables was $15.0 million for Q4 2016 at Teva Pharmaceutical Industries, down from $75.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $75.0 million in Q4 2015 and bottomed at $15.0 million in Q4 2016.
  • Average Notes Payables over 3 years is $45.3 million, with a median of $46.0 million recorded in 2014.
  • The sharpest move saw Notes Payables soared 63.04% in 2015, then tumbled 80.0% in 2016.
  • Year by year, Notes Payables stood at $46.0 million in 2014, then skyrocketed by 63.04% to $75.0 million in 2015, then crashed by 80.0% to $15.0 million in 2016.
  • Business Quant data shows Notes Payables for TEVA at $15.0 million in Q4 2016, $75.0 million in Q4 2015, and $46.0 million in Q4 2014.